NASDAQ$INBX
Inhibrx Biosciences Inc · Q3 2025 earnings
Q3 2025 earnings · · Before market open · Investor relations
Briefing
Inhibrx Biosciences reported Q3 2025, revenue of $1.3M, net loss of $35.3M.
For Q3 2025, Inhibrx Biosciences reported revenue of $1.3M, a net loss of $35.3M. Management discusses operations, liquidity, and outlook in the quarterly filing.
- Revenue $1.3M.
- Net loss $35.3M.
- Inhibrx Biosciences MD&A covers cash runway, pipeline, and sector risks.
Headline financials
Revenue & EPS history
Inhibrx Biosciences Inc · Revenue · Quarterly
$0
Forward guidance
Clinical-stage biotech outlook centers on trial milestones, partnerships, and cash runway.
Tailwinds
- Pipeline progress and R&D prioritization.
- Cash and equivalents fund operations.
Headwinds
- Trial delay or failure risk.
- Potential dilution from future financings.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 7 quarterly earnings reports · overlaid with Q3 2025
-2.2%
Avg return
Earnings day
-0.4%
Avg return
5 days after
+1.4%
Avg return
30 days after
36%
8 / 22 earnings
Positive
+8.4%
Q2 2021
Best reaction
-17.4%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +0.2% | -13.9% | -33.7% | |
| Q3 2025 | +5.7% | +10.1% | +6.6% | |
| Q2 2025 | +1.9% | -2.4% | +16.8% | |
| Q1 2025 | -1.9% | -1.3% | +9.9% | |
| Q4 2024 | -0.7% | +1.8% | -18.7% | |
| Q3 2024 | -10.5% | -7.5% | -5.4% | |
| Q2 2024 | +0.4% | +10.8% | +34.0% | |
| Q1 2024 | -0.4% | — | — | |
| Q4 2023 | -7.4% | — | — | |
| Q3 2023 | +0.1% | — | — | |
| Q2 2023 | -17.4% | — | — | |
| Q1 2023 | -2.5% | — | — | |
| Q4 2022 | -0.8% | — | — | |
| Q3 2022 | -4.2% | — | — | |
| Q2 2022 | +7.4% | — | — | |
| Q1 2022 | -7.1% | — | — | |
| Q4 2021 | -1.6% | — | — | |
| Q3 2021 | -3.5% | — | — | |
| Q2 2021 | +8.4% | — | — | |
| Q1 2021 | +3.7% | — | — | |
| Q4 2020 | -13.6% | — | — | |
| Q3 2020 | -4.5% | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro